Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18472969 | 0.80 | MAPT (0.35) | CA2 | |
| SCHEMBL15598617 | 0.80 | CA2 (0.35) | CA2 | |
| SCHEMBL10064046 | 0.77 | — | — | |
| SCHEMBL15993816 | 0.77 | — | — | |
| SCHEMBL11805773 | 0.76 | THRB (0.39) | CA2 | |
| Ethane SCHEMBL8848560 | 0.74 | THRB (0.37) | CA2 | |
| SCHEMBL312534 | 0.73 | — | — | |
| SCHEMBL10050322 | 0.72 | CA2 (0.33) | CA2 | |
| SCHEMBL19537494 | 0.72 | CA2 (0.33) | CA2 | |
| SCHEMBL22459048 | 0.72 | ALDH1A1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | ICHNOS SCIENCES S.A. (CH) | 2023-01-12 | — | — | US | disclosed |
| EP-0527851-A1 | 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1993-02-24 | — | — | EP | disclosed |
| WO-1991017148-A1 | 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP4K2, MAP4K4 | CA2 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.